Abstract

AimsTo analyse dosimetric and clinical predictors for acute and late gastrointestinal toxicity following chemoradiotherapy of anal cancer. Materials and methodsConsecutive patients with locally advanced (T2 ≥4 cm – T4 or N+) anal cancer were selected from an institutional database (n = 114). All received intensity-modulated radiotherapy with concomitant 5-fluorouracil and mitomycin C. Gastrointestinal toxicity was retrospectively graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and bowel cavity, small bowel and large bowel were contoured. Dosimetric and clinical variables were tested for associations with acute grade ≥3 gastrointestinal toxicity and late grade ≥2 gastrointestinal toxicity using the Mann–Whitney test, area under receiver operating characteristic curve (AUC) and logistic regression. ResultsThe median follow-up was 40 months. Acute grade ≥3 gastrointestinal toxicity was seen in 51 (44.7%) of the patients; late grade ≥2 gastrointestinal toxicity was seen in 36 of the patients (39.6% of 91 patients with >1 year recurrence-free follow-up). Bowel cavity V30Gy was the best dosimetric predictor for acute gastrointestinal toxicity (AUC 0.633; P = 0.02). Large bowel V20Gy was the best dosimetric predictor for late gastrointestinal toxicity (AUC 0.698; P = 0.001) but showed no association with acute gastrointestinal toxicity. In multivariate logistic regression, increasing age was significantly associated with acute gastrointestinal toxicity; smoking and large bowel V20Gy were significantly associated with late gastrointestinal toxicity. Patients who experienced acute grade ≥3 gastrointestinal toxicity were not at an increased risk of late grade ≥2 gastrointestinal toxicity (odds ratio 1.3; P = 0.55). ConclusionsFactors of importance for acute and late gastrointestinal toxicity were not the same. Bowel cavity V30Gy is a good metric to use for the prediction of acute gastrointestinal toxicity, but the results of our study indicate that individual large and small bowel loops need to be contoured for better prediction of late gastrointestinal toxicity. The role of the large bowel as an important organ at risk for late gastrointestinal toxicity merits further research.

Highlights

  • 114 patients with locally advanced anal cancer were treated with intensity-modulated radiotherapy (IMRT) and concomitant Fluorouracil and mitomycin C (FUMI)-based chemotherapy (Figure 1, Table 1)

  • Our results indicate that it seems sufficient to use the bowel cavity for risk prediction regarding acute gastrointestinal toxicity, but that individual large bowel loops need to be contoured for better prediction of late gastrointestinal toxicity

  • In accordance with the results of previous anal cancer studies, we found that bowel cavity V30Gy was the best dosimetric predictor for acute grade !3 gastrointestinal toxicity

Read more

Summary

Introduction

5-Fluorouracil and mitomycin C (FUMI)-based chemoradiotherapy (CRT) is an effective treatment for squamous cell carcinoma of the anus (anal cancer), with a chance of cure exceeding 70% [1,2]. The risk of severe toxicity is not the same for all patients; it is modified by clinical and dosimetric factors [7e14]. M.P. Nilsson et al / Clinical Oncology xxx (xxxx) xxx studies on dosimetric and clinical predictors for toxicity are much needed. Nilsson et al / Clinical Oncology xxx (xxxx) xxx studies on dosimetric and clinical predictors for toxicity are much needed Another important question in everyday clinical practice is which OARs should be delineated. The aim was to analyse clinical and dosimetric predictors for acute grade !3 gastrointestinal and late grade !2 gastrointestinal toxicity. The aim was to investigate if small bowel and large bowel significantly improved the toxicity prediction over and above bowel cavity

Materials and Methods
Results
Discussion
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call